Pramlintide — Complete Research Guide (2026)

Last updated 2026-06-30

What is Pramlintide?

Pramlintide is a synthetic analog of the beta-cell hormone amylin, FDA-approved as an adjunct to mealtime insulin in adults with type 1 or type 2 diabetes who have not reached glucose goals on insulin alone.

It carries an FDA boxed warning because co-administration with insulin can cause severe insulin-induced hypoglycemia, typically within three hours of dosing.

Its efficacy is supported by multiple 6-to-12-month randomized controlled trials in humans.

How does Pramlintide work?

Pramlintide mimics amylin by slowing gastric emptying, suppressing inappropriate postprandial glucagon secretion, and increasing satiety, which blunts after-meal glucose spikes.

These actions complement insulin and often produce modest weight loss rather than the weight gain seen with insulin alone.

What does the research say about Pramlintide?

• As a mealtime adjunct to insulin in type 1 diabetes, pramlintide reduced HbA1c and body weight over 12 months versus placebo. ^[1]
• In insulin-treated type 2 diabetes, pramlintide improved long-term glycemic control and reduced weight over one year. ^[2]
• Added to intensive insulin therapy in type 1 diabetes, pramlintide lowered postprandial glucose and body weight. ^[4]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

• [1] Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial — Ratner RE et al., Diabetic Medicine 2004. (1-year randomized controlled trial)
• [2] Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial — Hollander PA et al., Diabetes Care 2003. (1-year randomized controlled trial)
• [3] A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes — Whitehouse F et al., Diabetes Care 2002. (Randomized controlled trial with open-label extension)
• [4] A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes — Edelman S et al., Diabetes Care 2006. (Double-blind placebo-controlled RCT)
• [5] Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin — Riddle M et al., Diabetes Care 2007. (Randomized controlled trial)
• [6] Pramlintide in the treatment of type 1 and type 2 diabetes mellitus — Ryan GJ et al., Clinical Therapeutics 2005. (Narrative review)

Dosing context

In practice pramlintide is given by subcutaneous injection before major meals, started low and titrated up, with a simultaneous reduction in mealtime insulin to limit hypoglycemia risk.

This is general context only, not a dosing recommendation; exact dosing depends on diabetes type and must be set and supervised by a prescribing clinician.

Side effects & safety profile

Boxed warning: pramlintide used with insulin can cause severe hypoglycemia, most often within three hours of injection, which can impair driving or operating machinery; mealtime insulin is typically reduced by about half when starting.

Nausea is the most common side effect and usually lessens over time with gradual dose escalation.

It is injected separately from insulin (never mixed) and is not recommended in people with hypoglycemia unawareness, gastroparesis, or poor compliance with glucose monitoring.

Stacking & combinations

Its only established combination is with mealtime insulin, and that pairing requires insulin dose reduction and close glucose monitoring because of the hypoglycemia boxed warning.

Finding Pramlintide vendors

User reviews

Frequently asked questions

References

1. [1] Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial — Ratner RE et al., Diabetic Medicine 2004. PMID: 15498087. View sourceStudy: 1-year randomized controlled trialPramlintide added to insulin lowered HbA1c and body weight over 12 months in type 1 diabetes.
2. [2] Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial — Hollander PA et al., Diabetes Care 2003. PMID: 12610038. View sourceStudy: 1-year randomized controlled trialPramlintide improved HbA1c and reduced weight over one year in insulin-treated type 2 diabetes.
3. [3] A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes — Whitehouse F et al., Diabetes Care 2002. PMID: 11919132. View sourceStudy: Randomized controlled trial with open-label extensionLong-term pramlintide adjunct therapy improved glycemic control in type 1 diabetes.
4. [4] A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes — Edelman S et al., Diabetes Care 2006. PMID: 17003291. View sourceStudy: Double-blind placebo-controlled RCTPramlintide reduced postprandial glucose and weight when added to intensive insulin therapy in type 1 diabetes.
5. [5] Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin — Riddle M et al., Diabetes Care 2007. PMID: 17698615. View sourceStudy: Randomized controlled trialPramlintide added to basal insulin improved glycemic control and reduced weight in type 2 diabetes.
6. [6] Pramlintide in the treatment of type 1 and type 2 diabetes mellitus — Ryan GJ et al., Clinical Therapeutics 2005. PMID: 16330288. View sourceStudy: Narrative reviewReviews pramlintide's amylin-based mechanism, efficacy, and hypoglycemia and nausea safety considerations.